Zobrazeno 1 - 10
of 319
pro vyhledávání: '"peptide receptor radionuclide therapy (PRRT)"'
Autor:
Leandra Piscopo, Emilia Zampella, Fabio Volpe, Valeria Gaudieri, Carmela Nappi, Erica Di Donna, Stefania Clemente, Antonio Varallo, Mariano Scaglione, Alberto Cuocolo, Michele Klain
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5617-5629 (2024)
The aim of the present study was to evaluate the safety and efficacy of radionuclide therapy with [177Lu]Lu-DOTA-TATE according to our single center experience at the University of Naples Federico II. For the present analysis, we considered 21 patien
Externí odkaz:
https://doaj.org/article/a2dee3d0e61b43c9b6b706b9d0bab36d
Autor:
Dominik Lisowski, Philipp E. Hartrampf, Natalie Hasenauer, Vera Nickl, Camelia-Maria Monoranu, Jörg Tamihardja
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation We report an unusual case of a patient with a malignant meningioma who developed multiple metastas
Externí odkaz:
https://doaj.org/article/120176e112dc4afea2e498b122ca8868
Autor:
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer, Richard P. Baum
Publikováno v:
Diagnostics, Vol 14, Iss 9, p 907 (2024)
The present report describes the history of a 58-year-old woman with a rapidly progressing neuroendocrine pancreatic tumor (initially G2) presenting with extensive liver, bone, and lymph node metastases. Previous treatments included chemotherapy, hem
Externí odkaz:
https://doaj.org/article/954bf3749ed14039a4459a0950bb60ba
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements made toward early diagnosis and novel treatments, there is an urgent need to reduce its mortality. The Gastrin-Releasing Peptide Receptor (GRPR) is a promising targe
Externí odkaz:
https://doaj.org/article/d800166837b94aada0fe363fec5401d8
Autor:
Nils Florian Trautwein, Johannes Schwenck, Johann Jacoby, Gerald Reischl, Francesco Fiz, Lars Zender, Helmut Dittmann, Martina Hinterleitner, Christian la Fougère
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Aim/introductionPeptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS)
Externí odkaz:
https://doaj.org/article/608e55b2203e4f3e9540bddda76b7f37
Publikováno v:
Tomography, Vol 8, Iss 1, Pp 356-363 (2022)
High-concentrated amino acid solution is used to protect the kidneys during peptide receptor radionuclide therapy (PPRT) in patients with neuroendocrine tumors (NETs). Extravasation of the solution can cause cutaneous complications. In this study, we
Externí odkaz:
https://doaj.org/article/a380124d10c94d9b82468ee630d4e674
Autor:
Kevin A. Honan, Saamir Hassan, Anita Deswal, Joerg Herrmann, Juhee Song, Dominique Monlezun, Daniel Halperin, Armeen Mahvash, Arvind Dasari, Efstratios Koutroumpakis, Mehmet Akay, Dinu-Valentin Balanescu, Ismael Salas de Armas, Manish Patel, Sriram Nathan, Biswajit Kar, Konstantinos Marmagkiolis, Juan Lopez-Mattei, Jay Patel, Igor Gregoric, James Yao, Cezar A. Iliescu
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2023)
BackgroundCarcinoid heart disease (CnHD) is a frequent cause of morbidity and mortality in patients with neuroendocrine tumors and carcinoid syndrome. Although valve replacement surgery appears to decrease all-cause mortality in patients with advance
Externí odkaz:
https://doaj.org/article/7e6653e1a92a45efa6c1581f13d9dc27
Autor:
Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (
Externí odkaz:
https://doaj.org/article/2bbd26c1e218460f83eba0de87ee8bb0
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation carri
Externí odkaz:
https://doaj.org/article/2498b7ea891248fd94530d74a2fdd8a0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.